Imagin Medical Inc. IMEXF Archives - Page 2 of 6

WednesdayJun 09, 2021 12:21 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Aims for New Standard of Care in Visualizing Cancer

Imagin Medical’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging System(TM) is designed to enhance tumor visualization and resection, potentially lowering recurrence rates. With a focus on establishing a new standard of care in the visualization of cancer during minimally invasive procedures, Imagin Medical is initially targeting bladder cancer, the sixth most prevalent cancer in the U.S. and the third most common in men. Imagin’s i/Blue Imaging System aims to enhance the capabilities of cystoscopies, the conventional method used to visualize bladder cancer during surgical procedures. “Combining the effectiveness of blue light cystoscopy with proprietary technology, the i/Blue Imaging System will improve…

FridayJun 04, 2021 9:15 am

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Working to Make Blue Light Cystoscopy Easier to Use and More Accessible to Hospitals and Patients at a Lower Cost

Imagin Medical Inc. has designed a system to improve the visualization of bladder cancer during minimally invasive surgery that will display, simultaneously, white and blue light images side-by-side, to help surgeons more easily identify and locate cancerous tumors for removal The company’s i/Blue Imaging System(TM) has the potential to make bladder cancer detection and removal more efficient and accurate, as well as reduce recurrence rates and health care costs, targeting a global bladder cancer market estimated to reach $4.71 billion by 2026 The company’s proprietary system has entered the manufacturing stage with their partner Lighthouse Imaging, an FDA registered and…

WednesdayMay 26, 2021 1:00 pm

QualityStocksNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Breakthrough Cancer Visualization Technology Holds Significant Potential

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is looking to change how cystoscopies for bladder cancer are performed with the goal of potentially lowering recurrence rates and ultimately helping improve patients’ lives and long-term outlook. “The company’s i/Blue Imaging System(TM) is a breakthrough cancer visualization technology currently in the manufacturing stage with Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified contract manufacturer located in Maine. The project is on track for completion in 2022,” reads a recent article on the innovative solution. “Imagin Medical’s i/Blue Imaging System has the potential to revolutionize current cystoscopies by showing…

WednesdayMay 19, 2021 10:24 am

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Announces On-Track Progress for Demonstration of i/Blue Imaging System(TM)

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Per the update, the company is on target to demonstrate the i/Blue Imaging System(TM) in private meetings during the American Urology Association (“AUA”) meeting to be held in early September. The product will showcase updates to meet performance criteria against competitive products and enhancements made to the design for manufacturing. “As the process moves forward, we’re creating the potential for additional IP that will…

TuesdayMay 18, 2021 2:59 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Eyes ‘Exceptional’ Work to Move i/Blue Imaging System(TM) into Commercial Manufacturing

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, was featured in a recent article that discussed its timely progress toward 2022 completion of its innovative i/Blue Imaging System(TM). The patented system is designed leveraging proprietary light sensors and optics to improve the efficiency and accuracy of bladder cancer visualization and removal. According to the update, the on-track progress can be largely attributed to the company’s selection of Lighthouse Imaging as its manufacturing partner. “Lighthouse’s development program is focused on refining the i/Blue system’s design to ensure that the final device complies with all regulatory standards while maintaining optimal…

MondayMay 17, 2021 9:00 am

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Technology, will Potentially Reduce High Bladder Cancer Recurrence Rates

Approximately 50% of patients who have bladder cancer will see a recurrence of the condition – often due to poor margin visibility White light has been the standard procedure during cystoscopies, but is only beneficial if tumors protrude from the bladder wall Blue light cystoscopies address this issue, increasing the odds of removing more cancerous cells and reducing the recurrence of the cancer The i/Blue Imaging System(TM) improves surgical technique by combining both white and blue light capabilities on one screen without the necessity of switching between two images Imagin Medical Inc. is currently moving toward commercializing the system, expecting…

ThursdayMay 13, 2021 1:23 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Working Towards a Better Future for Bladder Cancer Patients

Bladder cancer is still the sixth most prevalent cancer in the U.S. in 2021 The total number of new bladder cancer cases is expected to reach 83,730, with deaths totaling 17,200 this year Imagin Medical Inc. is hoping to offer a better standard of care for bladder cancer patients with its i/Blue Imaging System(TM) that improves visualization for resection, potentially lowering recurrence rates According to American Cancer Society statistics, the number of cases of all types of cancer this year will total almost 1.9 million, with 608,570 deaths, or approximately 5,200 new cases and 1,670 deaths per day (https://ibn.fm/eDdCz). Of…

WednesdayMay 12, 2021 11:37 am

Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging System(TM) on Schedule for Completion in 2022

Imagin Medical’s contract manufacturer, Lighthouse Imaging, has developed a program focused on refining the i/Blue System’s design for manufacturing Lighthouse’s manufacturing process will ensure that regulatory standards are followed while maintaining optimal performance and staying within targeted costs Imagin is currently focusing on using the i/Blue system for bladder cancer visualization with plans to extend the use of the technology to other procedures in the future Imagin Medical (CSE: IME) (OTCQB: IMEXF) is on track to complete its patented i/Blue Imaging System(TM) in 2022. The innovative technology leverages proprietary light sensors and optics to improve the accuracy and efficiency of…

FridayMay 07, 2021 1:41 pm

QualityStocksNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue(TM) Imaging System to Enable More Accurate Tumor Resection

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has made notable strides in its quest to offer innovative technology for visualizing cancer. Designed to address the limitations of both white and blue light cystoscopy procedures, IME’s i/Blue(TM) Imaging System displays real-time white and blue light images on the screen simultaneously. This eliminates the need for the surgeon to switch back and forth between images, as is the case with blue light cystoscopy. On the other hand, it addresses the limitation of the white light cystoscopy, which is notorious for not clearly defining the margins between flat tumor and…

WednesdayApr 28, 2021 10:01 am

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Technology Development is at the Forefront of Bladder Cancer Visualization Innovation

The i/Blue Imaging System’s(TM) development is the first to harness the power of white light and blue light visualization techniques with the added capability of displaying multiple images simultaneously which will help surgeons perform more accurate tumor resections Imagin Medical’s innovative system is currently in the manufacturing phase with Lighthouse Imaging with product completion slated for 2022 With its patented technology, the company is positioned to stake a claim on a $400 million segment of the $46 billion global endoscopy market Advancements in the way that cancer is diagnosed and treated continue to be made. On the forefront of new…

Site Search

Company Search

Tag: Imagin Medical Inc. IMEXF